In wake of Covid-19 vaccine successes, Moderna scraps an mRNA-based antibody for chikungunya virus
Moderna has drawn plaudits from around the industry and the globe for its Covid-19 vaccine, and it reported continued financial success Thursday in its third-quarter report. But the biotech also quietly announced the discontinuation of another mRNA program, one in which it had collaborated with DARPA.
Execs are scrapping Phase II plans for an antibody directed at the chikungunya virus, the company announced Thursday, discreetly ending the development of a government-partnered product. Moderna did not provide a reason for the decision, saying only that a Phase I study had been completed and full results would be published “soon.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.